Welcome to our dedicated page for Koru Med Sys SEC filings (Ticker: KRMD), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
KORU Medical Systems filings document a Nasdaq-listed medical technology issuer focused on large-volume subcutaneous infusion products. The disclosures identify its common stock, operating results, earnings-release exhibits, non-GAAP measures such as adjusted EBITDA and adjusted diluted EPS, and the Freedom System product family used in home self-administration and ambulatory infusion settings.
Its SEC record also covers proxy governance, board and stockholder-meeting procedures, officer and compensation arrangements, and material agreements tied to the business. Recent 8-K filings describe credit-facility arrangements and manufacturing and supply agreements for subassemblies, needle sets, and tubing products.
KORU Medical Systems, Inc. reported first-quarter 2026 net revenues of $11.8 million, up 22.1% from $9.6 million a year earlier, driven by growth across domestic, international, and pharma services businesses. Domestic core revenue rose 11.7%, international core grew 35.2%, and pharma services and clinical trials increased 166.0%.
Gross profit increased to $7.2 million, although gross margin slipped to 61.5% from 62.8% due to higher production costs and tariff-related charges. Operating expenses rose 11.0% to $8.1 million, mainly from higher legal and compensation costs. Net loss narrowed to $0.8 million, or $0.02 per share, compared with a $1.2 million loss, or $0.03 per share, in the prior-year quarter.
The company ended the quarter with $8.8 million in cash and cash equivalents and $4.5 million of inventory, and generated essentially break-even operating cash flow. KORU amended its $10 million credit facility, extending maturities, lowering the interest rate floor to 5.50%, and lengthening the interest-only period on the term loan. The company expects existing cash, operations, and available credit to fund its needs for at least the next twelve months.
KORU Medical Systems reported strong first quarter 2026 growth while remaining modestly loss-making. Net revenues rose 22.1% to $11.8 million, driven by 11.7% domestic core growth to $7.7 million, 35.2% international core growth to $3.3 million, and 166.0% growth in pharma services and clinical trials to $0.7 million.
Gross profit increased to $7.2 million, though gross margin slipped to 61.5% from 62.8% due to higher production costs and tariff-related charges. Net loss improved to $0.8 million, or $0.02 per diluted share, from $1.2 million, or $0.03 per diluted share, with adjusted EBITDA near breakeven at negative $0.01 million.
Cash and cash equivalents were $8.8 million as of March 31, 2026, with minimal cash usage of about $0.1 million in the quarter. The company reiterated full-year 2026 guidance for net revenues of $47.5–$50.0 million, gross margin of 61–63%, and positive adjusted EBITDA and positive cash flow.
BlackRock, Inc. filed an amendment to a Schedule 13G reporting beneficial ownership of 2,292,477 shares of Koru Medical Systems Inc. The filing states BlackRock has 2,256,191 shares of sole voting power, represents 4.9% of the class, and is signed by a Managing Director.
KORU Medical Systems, Inc. is holding its 2026 Annual Meeting of Shareholders on May 19, 2026, asking holders of 47,490,432 common shares as of March 16, 2026 to vote on key governance and compensation items.
Shareholders will elect seven directors, approve on an advisory basis executive pay and the frequency of future say‑on‑pay votes, and ratify Cherry Bekaert LLP as independent auditor. They are also asked to approve an amendment to the 2024 Omnibus Equity Incentive Plan that doubles the share pool from 2,300,000 to 4,600,000 shares, plus shares that may return from older plans, to support future equity awards for employees, directors and consultants.
Manko Joseph M. Jr. reported acquisition or exercise transactions in this Form 4 filing.
KORU Medical Systems insider group reported an additional share award. On March 31, 2026, an entity identified as Horton Capital Partners Fund, L.P., which is associated with a ten percent owner, received a grant of 3,472 shares of Common Stock at $0.00 per share, reported as indirect ownership.
The filing also shows that, after this award, the indirectly held position reported for this fund stands at 5,065,970 shares of KORU Medical Systems Common Stock, while a separate direct holding line reflects 782,547 shares. This amendment mainly updates the recorded ownership levels rather than reflecting open‑market trading activity.
KORU Medical Systems, Inc. amended its loan and security agreement with HSBC Ventures USA Inc. covering a $5,000,000 revolving credit facility and a $5,000,000 term loan. The company has not drawn on this credit facility and is not required to do so.
The amendment extends the revolver maturity from December 31, 2026 to March 30, 2028 and the term loan maturity from December 1, 2028 to December 1, 2029. It also extends the term loan interest-only period to June 30, 2027, with a possible extension to December 31, 2027 if certain EBITDA milestones are met, lowers the interest rate floor to 5.50% from 6.50%, removes the adjusted quick ratio covenant, and adds a remaining months liquidity covenant of at least twelve months once the revolver is drawn.
Matin Shahriar reported acquisition or exercise transactions in this Form 4 filing.
KORU Medical Systems director Matin Shahriar received a compensation-related grant of 3,472 shares of common stock at an indicated value of $4.32 per share. After this award, he directly holds 97,573 common shares. This was an equity grant, not an open-market stock purchase or sale.
French Donna reported acquisition or exercise transactions in this Form 4 filing.
KORU Medical Systems director Donna French received a grant of Common Stock reported in a Form 4. She was awarded 3,472 shares at a value of $4.32 per share as a compensation-related grant, not an open-market purchase. Following this award, she directly holds 94,943 shares of KORU Medical Systems common stock.
KORU Medical Systems director Edward Wholihan received an award of 3,472 shares of Common Stock of KORU Medical Systems, Inc. The shares were granted at a price of $4.32 per share and are reported as directly owned.
Following this grant, Wholihan now directly holds 47,741 shares of Common Stock. This was recorded as a grant, award, or other acquisition on a Form 4 insider transaction report, rather than an open-market purchase or sale.